Condition: Locally Advanced Rectal Cancer (LARC) · Sponsor: National Cancer Institute, Naples
This is an observational, retrospective-prospective, multicentre trial enrolling all patients included in the AIFA monitoring registry of Dostarlimab for the indication in rectal cancer. The aims of the study are to describe the clinical outcomes and safety of patients with dMMR/MSI-H locally advanced rectal cancer (LARC) receiving neoadjuvant dostarlimab in the real-world setting.
This description comes directly from the study's public registry record.
Maria Carmela Piccirillo, MD · +39 08117770280 · m.piccirillo@istitutotumori.na.it
Piera Gargiulo, MD · +39 081 1777 0279 · piera.gargiulo@istitutotumori.na.it
Always discuss trial participation with your own doctor first.
| ASL Napoli 1, Presidio Ospedaliero Ospedale del mare, Oncologia medica | Naples, Italy | Not Yet Recruiting |
| IRCCS Fondazione G. Pascale, Unità Operativa Complessa Oncologia Addominale | Naples, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07269249